AP Anthony Bosch

Who is Anthony Bosch?

40 Comments

In the wake of ESPN’s Tuesday night report about Major League Baseball’s investigation and potential suspension of as many as two dozen players linked to the Biogenesis clinic in Miami, the spotlight has shone on one man more than any other: Anthony Bosch, the owner of the Biogenesis of America clinic and now the man who is reportedly prepared to turn over everything he knows about his famous clients to Major League Baseball.

But who is Anthony Bosch? What do we know about him?

Not much. We know he was born in Miami and grew up in comfortable circumstances. His father, Pedro Bosch, has been a successful physician for nearly 40 years. He has had multiple marriages and multiple failed businesses, with Biogenesis being the last.

Biogenesis was an “anti-aging” clinic that, superficially anyway, was like many in Florida. It was just across U.S. 1 from the University of Miami, housed in what was once a motel. Like other anti-aging clinics, it was a quasi-medical establishment which offered its mostly wealthy clients assistance in weight loss, physical fitness, and in some cases psychological services. Better living through therapy and chemistry. Such clinics are not licensed or regulated by the State of Florida.

The “quasi” part of that comes from the fact that Bosch is not a physician. His only known degree was obtained in 2009 from the Central America Health Sciences University in Belize, which he claimed to be a medical degree and displayed it on his office wall. According to the Miami New Times he wore a lab coat with “Dr. Tony Bosch” on it and gave the impression to many that he was, in fact, a doctor.

He did something else only doctors are allowed to do: as the New York Times reported in February, Bosch would obtain prescription drugs for his patients, including human growth hormone. His methods of doing so is unknown and are subject to an investigation by the Florida Department of Health and referrals to the Miami State Attorney’s office and the Florida Attorney General’s office. The New York Times report on Biogenesis in February described Bosch’s clinic as disheveled and disorganized. A former business partner of Bosch’s was surprised that Bosch was alleged to have worked with high-profile athletes, saying “I don’t know how the guy can tie his shoes, let alone have A-Rod as a client.”

But his business records, obtained by the Miami New Times suggest that he did indeed supply performance enhancing drugs to many ballplayers, A-Rod included. Most of the drug distributions were reported to have been made through intermediaries rather than to the ballplayers themselves. One of the alleged intermediaries was an employee of player agents the Levinson brothers. In the case of Alex Rodriguez, however, Bosch is alleged to have actually injected the player personally, doing so at Rodriguez’s home. All involved have denied the allegations.

Bosch himself denied any allegation that he supplied performance enhancing drugs to players, telling ESPN in April that such allegations are lies:

“I have been accused, tried and convicted in the media. And so I think have been falsely accused throughout the media … I am a nutritionist. I don’t know anything about performance-enhancing drugs.”

But that has all changed now. Major League Baseball sued Bosch in March, alleging that he tortiously interfered with baseball’s Joint Drug Agreement, damaging the game. On Thursday morning it was reported that, some time after that suit was filed, Bosch approached Alex Rodriguez in an effort to obtain his financial assistance in the face of the lawsuit and other investigations into his activities. Rodriguez is reported to have denied any assistance to Bosch.

Now, Bosch and Major League Baseball are reported to have come to an agreement in which the lawsuit will be dismissed against him, he will provide testimony and documents to Major League Baseball in furtherance of its investigation into Biogenesis-connected ballplayers and will indemnify him for any legal repercussions occasioned by his cooperation. While the baseball officials have not yet spoken to Bosch, it is reasonable to assume that the league’s cooperation with Bosch is based on him providing information which would implicate ballplayers in the use of performance enhancing drugs.

Angels ink Javy Guerra to minor league deal

Screenshot 2016-02-10 at 7.43.02 PM
Rich Pilling/Getty Images North America
Leave a comment

Mike DiGiovanna of the Los Angeles Times reports that the Angels have agreed to terms on a minor league contract with right-handed reliever Javy Guerra. The deal includes an invitation to major league spring training.

Guerra was suspended 50 games by Major League Baseball last July after testing positive for a drug of abuse. That suspension is now over, though Guerra is probably ticketed for the Angels’ Triple-A affiliate to begin the 2016 season.

The 30-year-old made just three major league appearances in 2015 for the White Sox before getting outrighted off Chicago’s 40-man roster. He does own a 2.87 ERA in 150 1/3 career innings, but it has come with bouts of inconsistency and unreliability.

Maybe he can get everything going in the right direction with Anaheim.

Braves sign reliever Carlos Torres

Screenshot 2016-02-10 at 7.00.22 PM
Rich Schultz/Getty Images North America
Leave a comment

As first reported by Bill Shanks of Fox Sports 1670, the Braves have signed right-handed reliever Carlos Torres to a minor league contract with an invitation to spring training.

Torres was waived by the Mets in January, somewhat surprisingly, and elected to become a free agent. The 33-year-old ultimately chose Atlanta, where he should have a good shot at an Opening Day roster out of spring training with the rapidly-rebuilding Braves.

Torres posted an ugly 4.68 ERA in 57 2/3 innings last season for the Mets, but he registered a gorgeous 3.06 ERA and 96 strikeouts across 97 innings in 2014.

If he gets off to a good start in 2016, he could become valuable trade bait.

Blue Jays will have a closer competition this spring

Screenshot 2016-02-10 at 6.22.24 PM
Tom Szczerbowski/Getty Images North America
3 Comments

Roberto Osuna became the youngest pitcher to ever play for the Blue Jays last season at age 20 and he rose to the challenge with a 2.58 ERA, 0.92 WHIP, and 75/16 K/BB ratio in 69 2/3 frames. Osuna eventually took over as Toronto’s closer, earning 20 regular-season saves and one in the American League Division Series — a five-out effort in Game 5 to close out the visiting Rangers.

But the Jays upgraded the back end of their bullpen this winter, acquiring Drew Storen from the Nationals in early January for speedy outfielder Ben Revere. Jesse Chavez was also brought to Toronto in a trade with the A’s.

Storen has more experience at closer than Osuna, and Storen struggled when the Nationals tried to put him in a setup role. Storen, in his final year of salary arbitration, also gets paid much more. He’s probably going to enter spring training as the favorite for the Jays’ ninth-inning gig, but there will be a competition …

Blue Jays general manager Ross Atkins told Ben Nicholson-Smith of Sportsnet.ca on Wednesday that he doesn’t expect the team to choose between Osuna or Storen until midway through spring training, if not later.

There’s been talk of making Osuna a starter, so add that wrinkle.

Storen, 28, boasts 95 career major league saves.

Orioles plotting late-offseason push? Gallardo, Fowler, Alvarez, Bruce in consideration

orioles logo
6 Comments

Baltimore’s front office appears to be lining up a run of potential roster additions leading into the beginning of spring training.

We’ve already passed along the reports suggesting they are close to a three-year deal with free agent starter Yovani Gallardo, but now FOX Sports’ Ken Rosenthal adds that free agent outfielder Dexter Fowler could be next on the Orioles’ target list. It they get those two deals done, the O’s could then chase free agent slugger Pedro Alvarez.

Rosenthal says the Orioles are even eyeing Jay Bruce of the Reds, though the FOX reporter hears the O’s might not have the prospects to pull off that kind of trade.

The focus for the Orioles out of the gate this winter was re-signing Matt Wieters and Chris Davis. Wieters accepted his one-year, $15.8 million qualifying offer in November and Davis was locked up to a seven-year, $161 million contract in mid-January.

Now the O’s are spending a little leftover cash on late-offseason additions to improve their position in what should be a tight 2016 American League East race.